ECSP055774A - Nuevo medicamento para el tratamiento de la enfermedad pulmonar obstructiva crónica - Google Patents

Nuevo medicamento para el tratamiento de la enfermedad pulmonar obstructiva crónica

Info

Publication number
ECSP055774A
ECSP055774A EC2005005774A ECSP055774A ECSP055774A EC SP055774 A ECSP055774 A EC SP055774A EC 2005005774 A EC2005005774 A EC 2005005774A EC SP055774 A ECSP055774 A EC SP055774A EC SP055774 A ECSP055774 A EC SP055774A
Authority
EC
Ecuador
Prior art keywords
pulmonary disease
chronic obstructive
obstructive pulmonary
treatment
new medication
Prior art date
Application number
EC2005005774A
Other languages
English (en)
Spanish (es)
Inventor
Sabine Pestel
Klaus Rudolf
Philipp Lustenberger
Thierry Bouyssou
Frank Buettner
Ingo Konetzki
Andreas Schnapp
Hermann Schollenberger
Kurt Schromm
Claudia Heine
Christoph Hoenke
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP055774(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ECSP055774A publication Critical patent/ECSP055774A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EC2005005774A 2002-11-15 2005-05-02 Nuevo medicamento para el tratamiento de la enfermedad pulmonar obstructiva crónica ECSP055774A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung

Publications (1)

Publication Number Publication Date
ECSP055774A true ECSP055774A (es) 2005-11-22

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005774A ECSP055774A (es) 2002-11-15 2005-05-02 Nuevo medicamento para el tratamiento de la enfermedad pulmonar obstructiva crónica

Country Status (38)

Country Link
EP (2) EP1562603B3 (enExample)
JP (1) JP4317138B2 (enExample)
KR (1) KR101092247B1 (enExample)
CN (3) CN101817800A (enExample)
AR (2) AR041969A1 (enExample)
AT (1) ATE430569T1 (enExample)
AU (1) AU2003285326B2 (enExample)
BE (1) BE2014C016I2 (enExample)
BR (1) BRPI0316264B8 (enExample)
CA (1) CA2506082C (enExample)
CO (1) CO5570670A2 (enExample)
CY (2) CY1110500T1 (enExample)
DE (2) DE10253282A1 (enExample)
DK (1) DK1562603T3 (enExample)
EA (1) EA008665B1 (enExample)
EC (1) ECSP055774A (enExample)
ES (1) ES2326878T7 (enExample)
FR (1) FR14C0049I2 (enExample)
HR (1) HRP20050432B1 (enExample)
HU (1) HUS1400011I1 (enExample)
IL (1) IL167900A (enExample)
LT (1) LTC1562603I2 (enExample)
LU (1) LU92433I2 (enExample)
ME (1) ME00354B (enExample)
MX (1) MXPA05005081A (enExample)
MY (1) MY136034A (enExample)
NL (1) NL300650I2 (enExample)
NO (2) NO334314B1 (enExample)
NZ (1) NZ540661A (enExample)
PE (1) PE20040694A1 (enExample)
PL (1) PL212238B1 (enExample)
PT (1) PT1562603E (enExample)
RS (1) RS51607B (enExample)
SI (1) SI1562603T1 (enExample)
TW (1) TWI343812B (enExample)
UA (1) UA81276C2 (enExample)
WO (1) WO2004045618A2 (enExample)
ZA (1) ZA200502246B (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
NZ550797A (en) * 2004-04-22 2010-08-27 Boehringer Ingelheim Int Pharmaceutical combinations containing 6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethylethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one for treating respiratory diseases
EP1789394A1 (de) * 2004-05-13 2007-05-30 Boehringer Ingelheim International Gmbh Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) * 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
US7994211B2 (en) 2005-08-08 2011-08-09 Argenta Discovery Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
DK1917253T3 (da) * 2005-08-15 2015-03-30 Boehringer Ingelheim Int Fremgangsmåde til fremstilling af betamimetika
TWI396541B (zh) * 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
US20070088030A1 (en) * 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
EP1948186A1 (en) * 2005-11-09 2008-07-30 Boehringer Ingelheim International Gmbh Aerosolformulation for inhalation
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
JP2009526817A (ja) * 2006-02-16 2009-07-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療用医薬組成物
PE20080142A1 (es) 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
RU2457209C2 (ru) 2006-04-21 2012-07-27 Новартис Аг Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
WO2008017638A1 (de) * 2006-08-07 2008-02-14 Boehringer Ingelheim International Gmbh Enantiomerenreine betaagonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
MX2009003185A (es) 2006-09-29 2009-04-03 Novartis Ag Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
HRP20110201T1 (hr) 2007-01-10 2011-08-31 Irm Llc Spojevi i sastavi kao inhibitori proteaze kanalizirane aktivacije
NZ579007A (en) * 2007-01-25 2012-02-24 Boehringer Ingelheim Int Method for producing betamimetics
DE602008005140D1 (de) 2007-05-07 2011-04-07 Novartis Ag Organische verbindungen
AR069637A1 (es) 2007-12-10 2010-02-10 Novartis Ag Derivados de pirazinas
CN101910153B (zh) 2008-01-11 2014-01-22 诺华股份有限公司 作为激酶抑制剂的嘧啶类
WO2009150137A2 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
PL2379507T3 (pl) 2008-12-30 2014-03-31 Pulmagen Therapeutics Inflammation Ltd Związki sulfonamidu do leczenia zaburzeń układu oddechowego
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
JP2013508414A (ja) 2009-10-22 2013-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症および他の慢性疾患の治療のための組成物
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2618827B1 (en) * 2010-09-21 2021-06-02 Intekrin Therapeutics, Inc. Antidiabetic solid pharmaceutical compositions
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
CN103946221B (zh) 2011-09-16 2016-08-03 诺华股份有限公司 用于治疗囊性纤维化的杂环化合物
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
JP2015533131A (ja) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 咳を治療するためのベータ２−アドレナリン受容体作動薬
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
CN106458979B (zh) 2014-04-24 2020-03-27 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的氨基吡嗪衍生物
EP3134396B1 (en) 2014-04-24 2019-09-18 Novartis AG Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
BR112016023967A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
US20200069679A1 (en) 2016-12-12 2020-03-05 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol
HRP20211915T1 (hr) 2016-12-20 2022-03-18 Inke, S.A. Poboljšani postupak dobivanja r-6-hidroksi-8-[1-hidroksi-2-[2-(4-metoksifenil)-1,1-dimetiletilaminoetil]-2h-1,4-benzoksazin-3(4h)-on-hidroklorida
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
AU2020290094B2 (en) 2019-06-10 2024-01-18 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
PE20220346A1 (es) 2019-08-28 2022-03-14 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
US11304897B2 (en) 2020-06-09 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
WO2001083462A1 (de) * 2000-04-27 2001-11-08 Boehringer Ingelheim Pharma Kg Neue, langwirksame betamimetika, verfahren zu deren herstellung und deren verwendung als arzneimittel

Also Published As

Publication number Publication date
BRPI0316264B1 (pt) 2019-04-09
DE50311502D1 (de) 2009-06-18
JP4317138B2 (ja) 2009-08-19
ES2326878T3 (es) 2009-10-21
EP1562603B3 (de) 2014-01-08
AU2003285326A1 (en) 2004-06-15
CY2014032I1 (el) 2015-12-09
CN1713914A (zh) 2005-12-28
CY1110500T1 (el) 2015-04-29
KR20050075013A (ko) 2005-07-19
ES2326878T7 (es) 2014-03-11
HUS1400011I1 (hu) 2022-02-28
NL300650I2 (nl) 2017-11-02
NO334314B1 (no) 2014-02-03
PL212238B1 (pl) 2012-08-31
CY2014032I2 (el) 2015-12-09
HRP20050432B1 (en) 2012-01-31
ZA200502246B (en) 2006-01-25
PT1562603E (pt) 2009-06-18
AR087241A2 (es) 2014-03-12
LTC1562603I2 (lt) 2016-12-12
CA2506082A1 (en) 2004-06-03
SI1562603T1 (sl) 2009-10-31
MXPA05005081A (es) 2005-07-01
BR0316264A (pt) 2005-10-11
TW200423943A (en) 2004-11-16
NO2014005I1 (no) 2014-03-10
IL167900A (en) 2013-06-27
LU92433I2 (fr) 2014-06-24
MEP53608A (en) 2011-05-10
JP2006508140A (ja) 2006-03-09
EA200500715A1 (ru) 2005-12-29
CN101735166A (zh) 2010-06-16
AR041969A1 (es) 2005-06-01
AU2003285326B2 (en) 2009-06-04
CO5570670A2 (es) 2005-10-31
FR14C0049I2 (fr) 2015-07-24
EP1562603B1 (de) 2009-05-06
MY136034A (en) 2008-07-31
PL375270A1 (en) 2005-11-28
BE2014C016I2 (enExample) 2023-03-07
ATE430569T1 (de) 2009-05-15
EP2025338A1 (de) 2009-02-18
CA2506082C (en) 2011-06-21
NO20052883L (no) 2005-06-14
DE10253282A1 (de) 2004-05-27
BRPI0316264B8 (pt) 2021-05-25
PE20040694A1 (es) 2004-11-23
KR101092247B1 (ko) 2011-12-12
DK1562603T3 (da) 2009-09-07
WO2004045618A2 (de) 2004-06-03
HRP20050432A2 (en) 2006-06-30
WO2004045618A3 (de) 2004-09-30
NZ540661A (en) 2007-12-21
ME00354B (me) 2011-10-10
RS51607B (sr) 2011-08-31
TWI343812B (en) 2011-06-21
CN101817800A (zh) 2010-09-01
EP1562603A2 (de) 2005-08-17
EA008665B1 (ru) 2007-06-29
FR14C0049I1 (enExample) 2014-08-08
UA81276C2 (en) 2007-12-25
RS20050361A (sr) 2007-04-10

Similar Documents

Publication Publication Date Title
ECSP055774A (es) Nuevo medicamento para el tratamiento de la enfermedad pulmonar obstructiva crónica
UY28369A1 (es) Agentes terapéuticos
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
ECSP066948A (es) Benzoxazinas para el tratamiento de enfermedades de las vías respiratorias
WO2007022380A3 (en) Bis-aryl amide compounds and methods of use
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
ECSP088593A (es) 5-(arilsulfonil)-pirazolopiperidinas
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
EA200802173A1 (ru) Производные терфенила для лечения болезни альцгеймера
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
CY1111022T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
UY28861A1 (es) Nuevas combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
DK1641454T3 (da) Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
PA8532001A1 (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
ECSP066770A (es) Nuevos ésteres de quinuclidina cuaternizados
UY28896A1 (es) Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
ECSP099080A (es) Combinaciones farmacológicas para el tratamiento de enfermedades de las vías aéreas
UY29394A1 (es) Derivados sustituidos de n-(5-(2-propilamino.1.hidroxietil)-2-hdroxifenil) metano sulfonamida, composiciones farmacéuticas que lo contienen y aplicaciónes.
ECSP099082A (es) Beta-agonistas enantioméricamente puros, procedimientos para su preparación y su uso como medicamentos